Search Non-Antibody Products
|
|
|
|
|
Non-antibody Products (Kits, Proteins, Microbial Antigens, Tissues, Services, etc.) - Page 31 of 6,058
| Name |
Description |
Size |
Catalog # |
Supplier |
|
| Block Ace |
n/a |
20 x 4 g |
YSRTBUF029 |
 ACCURATE CHEMICAL & SCIENTIFIC CO. |
More Info
|
| AGKISTRODON BLOMHOFFI |
reptile venom |
n/a |
n/a |
MIAMI SERPENTARIUM LABS |
More Info
|
| alamarBlue |
alamarBlue is an indicator dye, that incorporates an oxidation-reduction (REDOX) indicator that both fluoresces and changes colour in response to the chemical reduction of growth medium, resulting from cell growth. The alamarBlue assay is designed... |
100 ml |
MBS238968 |
 MYBIOSOURCE, LLC |
More Info
|
| BMY 14802 |
General Sigma Receptor Antagonist |
10 mg |
1440/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMY 14802 |
General Sigma Receptor Antagonist |
50 mg |
1440/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BMY 45778 |
Prostanoid Receptor Agonist |
10 mg |
1442/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMY 45778 |
Prostanoid Receptor Agonist |
50 mg |
1442/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BMY 45778 |
Non-prostanoid prostacyclin mimetic that acts as a partial agonist at IP1 prostacyclin receptors. Potently inhibits platelet aggregation in vitro (IC50 = 27-35 nM). Minimum Purity: > 99% |
50mg |
1442 |
 TOCRIS BIOSCIENCE |
More Info
|
| BMY 45778 |
Non-prostanoid prostacyclin mimetic that acts as a partial agonist at IP1 prostacyclin receptors. Potently inhibits platelet aggregation in vitro (IC50 = 27-35 nM). Minimum Purity: > 99% |
10mg |
1442 |
 TOCRIS BIOSCIENCE |
More Info
|
| BML-190 |
Cannabinoid R2/CB2 Receptor Ligand |
10 mg |
1383/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BML-190 |
Cannabinoid R2/CB2 Receptor Ligand |
50 mg |
1383/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BML-190 |
Potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 µM for CB2 and CB1 respectively). Minimum Purity: > 99% |
10mg |
1383 |
 TOCRIS BIOSCIENCE |
More Info
|
| BML-190 |
Potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 µM for CB2 and CB1 respectively). Minimum Purity: > 99% |
50mg |
1383 |
 TOCRIS BIOSCIENCE |
More Info
|
| BML-210 |
Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation. BML-210 is a small molecule inhibitor of HDAC with... |
5 mg |
P013-5MG |
 ARBOR ASSAYS, LLC |
More Info
|
| BML-210 |
Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation. BML-210 is a small molecule inhibitor of HDAC with... |
25 mg |
P013-25MG |
 ARBOR ASSAYS, LLC |
More Info
|
| BML-278 |
Sirt activator based on a dihydropyridine structural scaffold. EC150 (effective concentration able to increase enzyme activity by 150%) is 1 uM for Sirt1, 25 uM for Sirt2, and 50 uM for Sirt3. The compound is active in whole cells and arrests cell... |
5 mg |
P003-5MG |
 ARBOR ASSAYS, LLC |
More Info
|
| BML-278 |
Sirt activator based on a dihydropyridine structural scaffold. EC150 (effective concentration able to increase enzyme activity by 150%) is 1 uM for Sirt1, 25 uM for Sirt2, and 50 uM for Sirt3. The compound is active in whole cells and arrests cell... |
25 mg |
P003-25MG |
 ARBOR ASSAYS, LLC |
More Info
|
| BMP3 |
Purity: >95% |
50 µg |
AR20013PU-N |
 ACRIS ANTIBODIES GmbH |
More Info
|
| BMP3 |
Purity: >95% |
10 µg |
AR20013PU-S |
 ACRIS ANTIBODIES GmbH |
More Info
|
| BMP3 |
Purity: >95% |
20 µg |
AR09436PU-N |
 ACRIS ANTIBODIES GmbH |
More Info
|
| BMP3 |
Purity: >95% |
5 µg |
AR09436PU-S |
 ACRIS ANTIBODIES GmbH |
More Info
|
| BMS 777607 |
BMS 777607 is a Small-Molecule Met Kinase Inhibitor with an IC50 of < 0.1 ?M. Purity is greater than 99%. |
10 mg |
orb60514 |
 BIORBYT LTD. |
More Info
|
| BMS 794833 |
BMS-794833 is a potent ATPcompetitive Met/VEGFR-2 kinase inhibitor and it also inhibits Ron (Met family),Axl and Flt-3 with IC50 values <3 nM. Purity is greater than 99%. |
10 mg |
orb60830 |
 BIORBYT LTD. |
More Info
|
| BMS-536924 |
BMS-536924 Purity is greater than 99%. |
10 mg |
orb60073 |
 BIORBYT LTD. |
More Info
|
| BMS-599626 |
BMS-599626 is a highly selective pan-HERKinase inhibitor with IC50 of 20 and 30 nM for the inhibition of HER1and HER2, respectively. Purity is greater than 99%. |
5 mg |
orb60108 |
 BIORBYT LTD. |
More Info
|
| BMS-707035 |
BMS-707035 is an HIV-1 integrase (IN) inhibitor. Purity is greater than 99%. |
10 mg |
orb60354 |
 BIORBYT LTD. |
More Info
|
| BMS-708163 |
?-secretase inhibitor (GSI) (IC50 =0.3 nM) Purity is greater than 99%. |
10 mg |
orb60280 |
 BIORBYT LTD. |
More Info
|
| BMS-740808 |
BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable blood coagulation factor Xa inhibitor with a Ki of 30 pM. Purity is greater than 99%. |
10 mg |
orb60520 |
 BIORBYT LTD. |
More Info
|
| BMS-790052 |
BMS-790052 is a first-in-class, highly-selective oral HCV NS5A inhibitor. Purity is greater than 99%. |
10 mg |
orb60456 |
 BIORBYT LTD. |
More Info
|
| BMS-599626 |
An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overex... |
1 mg |
1614-1 |
 BIOVISION, INC. |
More Info
|
| BMS-599626 |
An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overex... |
5 mg |
1614-5 |
 BIOVISION, INC. |
More Info
|
| BMS 191011 |
Ca2+-Activated Potassium Channel Activator |
10 mg |
2665/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 191011 |
Ca2+-Activated Potassium Channel Activator |
50 mg |
2665/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 193885 |
NPY Receptor Antagonist |
10 mg |
3242/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 193885 |
NPY Receptor Antagonist |
50 mg |
3242/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 195614 |
Retinoic Acid Receptor Antagonist |
10 mg |
3660/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 195614 |
Retinoic Acid Receptor Antagonist |
50 mg |
3660/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 299897 |
Secretase Inhibitor |
10 mg |
2870/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 453 |
n/a |
10 mg |
3409/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 493 |
Retinoic Acid Receptor Antagonist |
10 mg |
3509/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 493 |
Retinoic Acid Receptor Antagonist |
50 mg |
3509/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 753 |
Retinoic Acid Receptor Agonist |
10 mg |
3505/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 753 |
Retinoic Acid Receptor Agonist |
50 mg |
3505/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 961 |
Retinoic Acid Receptor Agonist |
10 mg |
3410/10 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 961 |
Retinoic Acid Receptor Agonist |
50 mg |
3410/50 |
 R&D SYSTEMS, INC. |
More Info
|
| BMS 191011 |
Potent Maxi-K channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1, BKCa). Neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke). Minimum Purity: > 99% |
50mg |
2665 |
 TOCRIS BIOSCIENCE |
More Info
|
| BMS 191011 |
Potent Maxi-K channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1, BKCa). Neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke). Minimum Purity: > 99% |
10mg |
2665 |
 TOCRIS BIOSCIENCE |
More Info
|
| BMS 193885 |
Potent, competitive neuropeptide (NPY) Y1 antagonist (Ki = 3.3 nM, IC50 = 5.9 nM) that displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over ?1, alpha1, Y2, Y4 and Y5 receptors respectively. Reduces food intake and body weight via cen... |
10mg |
3242 |
 TOCRIS BIOSCIENCE |
More Info
|
| BMS 193885 |
Potent, competitive neuropeptide (NPY) Y1 antagonist (Ki = 3.3 nM, IC50 = 5.9 nM) that displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over ?1, alpha1, Y2, Y4 and Y5 receptors respectively. Reduces food intake and body weight via cen... |
50mg |
3242 |
 TOCRIS BIOSCIENCE |
More Info
|
| BMS 195614 |
Neutral retinoic acid receptor (RAR) alpha-selective antagonist (Ki = 2.5 nM). Displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. Antagonizes agonist-induced coactivator (CoA) r... |
10mg |
3660 |
 TOCRIS BIOSCIENCE |
More Info
|
Search Non-Antibody Products
|